Complete coverage guide
Life sciences insurance: the complete coverage guide.
Life sciences insurance is the specialty insurance program built around the regulatory, contractual, and product-risk exposures unique to companies that develop, manufacture, test, distribute, or dispense pharmaceutical drugs, biologics, medical devices, diagnostic tests, or compounded therapeutics. It differs from generic commercial insurance in three structural ways: the coverage lines are sized to FDA-class product exposure rather than generic class codes; the contractual requirements (sponsor MSAs, GPO supplier agreements, PBM credentialing, hospital purchase contracts, clinical trial agreements, 503B outsourcing agreements) drive specific endorsement schedules generalist policies don\'t address; and the underwriting carriers active in the class are a narrow specialty set, not the broader admitted commercial market.
This guide covers: the twelve coverage lines a life sciences company actually needs, how those needs differ by company type (biotech, medical device, CDMO, CRO, compounding pharmacy, 503B, GLP-1 compounder, diagnostic lab), how they shift across company stage (pre-revenue → clinical → commercial → M&A), the seven most common gaps generalist brokers miss, and what to ask a specialty broker before signing. Educational only — coverage availability and pricing vary by carrier, state, operator size, product mix, and risk profile. Buyers should consult licensed counsel and a qualified specialty insurance broker for binding decisions.
Coverage lines
The twelve coverage lines a life sciences company needs.
Most operators carry a subset of these depending on company type, stage, and contractual obligations. Few operators need every line; almost no operators need fewer than five.
By company type
The coverage mix shifts materially by sub-vertical.
A pre-revenue clinical-stage biotech and a 503B outsourcing facility both fall under "life sciences," but the insurance programs share almost no overlap in priority or structure. The dominant coverage line and the dominant contractual driver differ for each sub-vertical:
CDMO Insurance (Pharma & Medical Device Contract Manufacturers)
Products liability ($5M-$10M), professional liability for cGMP work, sponsor MSA compliance, cargo for sponsor-supplied API, cyber for drug master file data.
Practice pageCRO Insurance (Contract Research Organizations)
Clinical trial liability, professional liability, cyber sized to PHI volume, sponsor MSA indemnification coordination.
Practice pageMedical Device Insurance (Class I/II/III Manufacturers)
Products liability tower (often $25M+ for implantables), MDR liability extension, GPO supplier compliance, cyber for connected devices.
Practice pageBiotech Insurance (Clinical-Stage Drug Companies)
D&O architecture (private then IPO/SPAC transactional), clinical trial liability with site additional insureds, employment practices, fiduciary, cyber, IP infringement.
Practice pageCompounding Pharmacy Insurance (503A Sterile/Non-Sterile)
Druggist professional liability, USP 797/800 compliance documentation, products liability, PBM credentialing requirements, GLP-1 carrier exclusion landscape.
Practice page503B Outsourcing Facility Insurance
Hospital purchase contract insurance compliance, Joint Commission MCC certification, cGMP property with validation loss endorsement, FDA recall extension, Vizient/Premier/HealthTrust schedules.
Practice pageGLP-1 Compounding Insurance
Products liability carrier exclusion review at renewal, market-mapping to carriers still writing the exposure, FDA enforcement risk.
Practice pageDiagnostic Lab Insurance (CLIA Clinical & Molecular)
Professional liability / E&O, cyber/HIPAA sized to PHI volume, bioanalytical method liability, hospital reference laboratory contracts.
Practice pageBy company stage
Insurance priorities shift across the lifecycle.
A pre-revenue biotech and a commercial-stage operator face different coverage triggers and different investor or counterparty demands. The structural shift is roughly:
Pre-revenue / pre-clinical
D&O (mandatory once VC funded), basic CGL, workers comp, cyber. Skip products liability and CTL until materially relevant. Property scoped to lab space.
Clinical-stage
Add clinical trial liability ahead of first-in-human dosing. D&O scales with funding round and pipeline disclosure cadence. Cyber scales with PHI and IND data volume. Professional liability if you offer development services to other sponsors.
Pre-commercial / launch
Add products liability ahead of commercial launch — sized to expected first-year revenue and product class. Add recall coverage as standalone. Scale D&O for transactional events (IPO, SPAC, partnership). Review all sponsor and hospital contracts in pipeline against schedule.
Commercial-stage
Products liability tower at full deployment scale. D&O at public-company sizing (Side A + Side B/C). Cyber at enterprise scale. Recall coverage with explicit FDA Class I/II/III. Employment practices liability scales with headcount.
M&A-active or transactional
Reps & warranties insurance for transactions. Runoff/tail D&O for acquired entities. Transaction-specific cyber and IP diligence. Sponsor and supplier contract assignment review.
Contractual triggers
Six contracts that drive most insurance schedule demands.
The single biggest source of insurance program friction in life sciences is a contract landing with an insurance schedule the operator\'s current program doesn\'t satisfy. The six contract types that most commonly trigger a rebuild:
- Sponsor Master Service Agreement (MSA) — drives CDMO and CRO insurance schedules. Typically demands products liability, additional-insured wording, primary/non-contributory, waiver of subrogation, 30-day notice of cancellation, sometimes professional liability for development scope.
- GPO Supplier Agreement (Vizient, Premier, HealthTrust) — drives medical device and 503B insurance schedules. Standardized templates enforced through Symplr/Reptrax credentialing platforms.
- Hospital Purchase Contract — direct (non-GPO) hospital purchasing agreements with IDNs and academic medical centers. Insurance schedules inherit from GPO templates but with hospital- specific customizations.
- PBM Credentialing Packet (Express Scripts, CVS Caremark, OptumRx) — drives 503A and 503B pharmacy network credentialing. Druggist professional liability and general liability minimums plus current COI on file.
- Clinical Trial Agreement (CTA) — drives biotech sponsor and CRO insurance schedules. Typically demands clinical trial liability with site and investigator additional-insured wording.
- 503B Outsourcing Agreement — direct supply contracts between 503B outsourcing facilities and hospital pharmacies. cGMP-aligned property, FDA recall extension, Joint Commission MCC attestation.
Our free Insurance Requirements Analyzer translates the insurance section of any of these six contracts into plain English with negotiability notes, and flags gaps against the operator\'s current program. A specialist returns a clause-by-clause review within one business day.
Common gaps
Seven gaps generalist brokers miss.
Most life sciences operators placed by generalist commercial brokers have at least one structural gap their current COI doesn\'t reveal. The seven that recur most often:
CMO scope-creeps into CDMO development work without adding professional liability/E&O.
Impact:A failed development batch produces pure economic loss; products liability excludes it; uninsured indemnity owed to sponsor falls on the balance sheet.
503B passes credentialing with CG 20 10 (ongoing-ops AI) but not CG 20 37 (products/completed-ops AI).
Impact:Hospital orders fail to ship via Symplr/Reptrax credentialing platform until the second endorsement is added.
Compounding pharmacy renewal endorsement schedule adds GLP-1 exclusion without prominent disclosure.
Impact:Products liability for GLP-1 revenue line is uninsured; carrier denies if claim hits; uncovered exposure on a high-revenue product.
Clinical-stage biotech renews D&O without addressing pre-IPO transactional gap.
Impact:Post-IPO stock-drop securities class action surfaces gap between renewal D&O and transactional D&O; coverage fight at the worst possible moment.
Medical device manufacturer carries products liability on claims-made form instead of occurrence form.
Impact:Long claim tail on implantables (often 10-20 years between manufacture and claim) exceeds claims-made coverage window; uncovered legacy product exposure.
CRO carries cyber at $1M for a sponsor portfolio with multi-million-PHI-record studies.
Impact:Single breach incident exhausts the cyber limit before notification expense is paid; sponsor indemnity comes out of pocket.
Generalist broker places life-sciences operator in standard manufacturer products policy without recall extension.
Impact:First Class II FDA recall reveals sublimited or absent recall coverage; uncovered recall costs run into millions.
What to ask a specialty broker
Eight questions before you bind.
- How many life sciences operators are you currently placing programs for in my sub-vertical?
- Which specialty markets are you accessing for products liability — admitted, surplus lines via wholesale, or both?
- Can you provide a sample sponsor MSA, GPO supplier agreement, or hospital purchase contract you\'ve walked a similar operator through, with the schedule gaps and resolutions documented?
- What\'s your process for reviewing my actual contracts in pipeline (not just my current COI) against carrier policy forms before binding?
- How do you handle the recall coverage question — embedded sublimit, standalone policy, or layered structure?
- Does your placement include professional liability/E&O as a standalone line, or is it bundled inside the CGL/products policy?
- What\'s the carrier appetite picture for my class right now — specifically for {GLP-1 / cGMP property / connected device cyber / IPO transactional D&O / etc.} — and how has it shifted in the last 12 months?
- What\'s your response SLA on a contract review or coverage question? (We commit to end of business day.)
Why specialty matters
Generalist brokers place life sciences operators on the wrong forms.
The most common failure mode in life sciences insurance is a generalist commercial broker placing an operator on a standard manufacturer or service-firm policy form. The COI looks compliant. The limits look right. The premium is competitive. Everything fails at first claim — products liability that excluded recall extensions, additional-insured wording that didn\'t cover products/completed operations, cyber that sublimited HIPAA breach response, professional liability missing because the operator was placed as a manufacturer.
The specialty market for life sciences insurance is narrow. A small number of carriers — both admitted and surplus-lines — actively underwrite the class with familiarity for cGMP, USP 797/800, FDA recall structures, clinical trial liability for first-in-human dosing, D&O for clinical-stage public biotech, hospital purchase contract insurance schedules, GPO supplier compliance, MDR liability extensions, and the rest of the specialized coverage forms life sciences operators actually need.
We do not name specific carriers on this site (Texas Department of Insurance advertising-rule compliance + agency-neutral positioning). What we can do is rebuild your program around the actual contract requirement, place it through carriers with documented life sciences appetite, and review every commercial contract in your pipeline against your bound program before you sign.
Resources on this site
Where to go deeper.
CDMO Insurance practice page — sponsor MSA insurance, products tower sizing, recall coverage
CRO Insurance practice page — clinical trial liability, professional liability, cyber for PHI
Medical Device Insurance practice page — GPO supplier compliance, MDR liability, connected device cyber
Biotech Insurance practice page — D&O for clinical-stage, CTA insurance schedules
Compounding Pharmacy practice page — druggist professional liability, USP 797/800
503B Outsourcing practice page — hospital purchase contract compliance, cGMP property
GLP-1 Compounding practice page — 2026 carrier exclusion landscape, re-papering
Diagnostic Lab practice page — CLIA labs, bioanalytical, hospital reference
Cost Guide — typical premium ranges by sub-vertical and revenue band
Clause Glossary — 49 hand-translated insurance clauses
Q&A Library — 23 long-form answers with primary-source citations
Insights blog — MSA requirements, recall, GLP-1, USP 797/800, 503B field guide
Free coverage review
A specialist will reach out by the end of the day.
Send your contract, sponsor insurance schedule, GPO supplier agreement, hospital purchase contract, or your current COI — whatever you have. A specialty insurance specialist returns a clause-by-clause review within one business day.